导致 HIV-2 对拉替拉韦产生耐药性的整合酶基因变异热点。
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
机构信息
Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, 46 Rue Henri Huchard, 75018 Paris, France.
出版信息
Antimicrob Agents Chemother. 2011 Mar;55(3):1293-5. doi: 10.1128/AAC.00942-10. Epub 2010 Dec 28.
Abstract
We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.
摘要
我们研究了 7 名接受挽救性含raltegravir 方案治疗但出现病毒学失败的重度预处理 HIV-2 感染者。在病毒学失败时，观察到不同的耐药遗传途径：T97A-Y143C、Q148K、Q148R、G140S-Q148R、E92Q-Y143R-N155H 和 T97A-N155H。因此，尽管 HIV-1 和 HIV-2 的整合酶基因有 40%的差异，但导致raltegravir 耐药的遗传途径相似。
相似文献
1
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.导致 HIV-2 对拉替拉韦产生耐药性的整合酶基因变异热点。
Antimicrob Agents Chemother. 2011 Mar;55(3):1293-5. doi: 10.1128/AAC.00942-10. Epub 2010 Dec 28.
2
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.G140S/Q148R 和 N155H 突变使 HIV-2 整合酶对拉替拉韦产生耐药性，而 Y143C 则不会。
Retrovirology. 2011 Aug 19;8:68. doi: 10.1186/1742-4690-8-68.
3
HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.HIV-2整合酶多态性及对含raltegravir方案治疗失败的HIV-2感染患者的纵向基因分型分析
PLoS One. 2014 Mar 28;9(3):e92747. doi: 10.1371/journal.pone.0092747. eCollection 2014.
4
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.在停用拉替拉韦后，HIV-2感染患者中整合酶耐药性突变的长期持续存在。
Antivir Ther. 2011;16(6):937-40. doi: 10.3851/IMP1826.
5
Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.HIV-2 对拉替拉韦的表型敏感性：整合酶突变 Q148R 和 N155H 导致拉替拉韦耐药。
AIDS. 2011 Nov 28;25(18):2235-41. doi: 10.1097/QAD.0b013e32834d8e52.
6
Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.接受雷特格韦挽救治疗失败的患者中HIV整合酶基因的耐药谱。
HIV Med. 2008 Oct;9(9):765-70. doi: 10.1111/j.1468-1293.2008.00628.x. Epub 2008 Jul 21.
7
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.1型人类免疫缺陷病毒对拉替拉韦的敏感性丧失是通过多种不重叠的遗传途径造成的。
J Virol. 2009 Nov;83(22):11440-6. doi: 10.1128/JVI.01168-09. Epub 2009 Sep 16.
8
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.与雷特格韦治疗失败相关的突变在体外会影响整合酶对该抑制剂的敏感性。
Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.
9
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.HIV-2 患者在使用雷特格韦失败时出现的耐药突变及其对多替拉韦反应的影响。
J Antimicrob Chemother. 2017 Jul 1;72(7):2083-2088. doi: 10.1093/jac/dkx090.
10
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.拉替拉韦治疗失败的经治患者中整合酶抑制剂耐药模式与 HIV-1。
J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12.
引用本文的文献
1
Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review.HIV-2中含整合酶链转移抑制剂的抗逆转录病毒疗法的临床结局：一项叙述性综述
Infect Dis Ther. 2024 Jun;13(6):1161-1175. doi: 10.1007/s40121-024-00982-7. Epub 2024 May 9.
2
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.抗逆转录病毒治疗 HIV-2 感染：现有药物、耐药途径和有前途的新化合物。
Int J Mol Sci. 2023 Mar 21;24(6):5905. doi: 10.3390/ijms24065905.
3
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.不同途径导致整合酶链转移抑制剂耐药。
Viruses. 2022 Nov 22;14(12):2591. doi: 10.3390/v14122591.
4
High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients.比替拉韦和新型螺环β-内酰胺 BSS-730A 对 RAL 初治和 RAL 失败的 HIV-2 分离株的高瞬时抑制潜能。
Int J Mol Sci. 2022 Nov 18;23(22):14300. doi: 10.3390/ijms232214300.
5
Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.拉替拉韦和多替拉韦对新型治疗相关 HIV-2 整合酶突变的活性谱：使用扩展的定点突变面板进行表型分析。
J Infect Dis. 2022 Aug 26;226(3):497-509. doi: 10.1093/infdis/jiac037.
6
Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.比较比替拉韦对 HIV-1 和 HIV-2 分离株以及整合酶抑制剂耐药的 HIV-2 突变体的抗病毒活性。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00014-19. Print 2019 May.
7
Different Pathways Leading to Integrase Inhibitors Resistance.导致整合酶抑制剂耐药性的不同途径。
Front Microbiol. 2017 Jan 11;7:2165. doi: 10.3389/fmicb.2016.02165. eCollection 2016.
8
The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.核苷类似物BMS-986001对HIV-2的体外活性比对HIV-1的活性更强。
Antimicrob Agents Chemother. 2015 Dec;59(12):7437-46. doi: 10.1128/AAC.01326-15. Epub 2015 Sep 21.
9
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.多替拉韦对野生型和整合酶抑制剂耐药HIV-2的体外活性。
Retrovirology. 2015 Feb 5;12:10. doi: 10.1186/s12977-015-0146-8.
10
Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.将HIV-1整合酶耐药性突变引入SIVmac239后对整合酶链转移抑制剂敏感性的影响。
J Virol. 2014 Sep 1;88(17):9683-92. doi: 10.1128/JVI.00947-14. Epub 2014 Jun 11.
本文引用的文献
1
Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.整合酶抑制剂耐药的进化：基于整合酶抑制剂的抗逆转录病毒治疗失败时。
J Acquir Immune Defic Syndr. 2010 Aug;54(4):389-93. doi: 10.1097/QAI.0b013e3181c42ea4.
2
HIV resistance to raltegravir.HIV 对拉替拉韦的耐药性。
Eur J Med Res. 2009 Nov 24;14 Suppl 3(Suppl 3):47-54. doi: 10.1186/2047-783x-14-s3-47.
3
Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.在病毒学失败期间对1型人类免疫缺陷病毒的拉替拉韦敏感性和整合酶复制能力的纵向分析。
Antimicrob Agents Chemother. 2009 Oct;53(10):4522-4. doi: 10.1128/AAC.00651-09. Epub 2009 Aug 10.
4
Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.HIV-2整合酶中的N155H突变赋予对raltegravir的高表型耐药性并损害复制能力。
J Clin Virol. 2009 Oct;46(2):173-5. doi: 10.1016/j.jcv.2009.06.020. Epub 2009 Jul 22.
5
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.HIV-1感染患者对拉替拉韦产生耐药性过程中的准种变异动态。
J Antimicrob Chemother. 2009 Apr;63(4):795-804. doi: 10.1093/jac/dkp014. Epub 2009 Feb 16.
6
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.在含雷特格韦且治疗失败的方案中选择Q148R整合酶抑制剂耐药突变。
AIDS. 2008 Oct 1;22(15):2045-6. doi: 10.1097/QAD.0b013e32830f4c7d.
7
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.HIV-2整合酶基因多态性及HIV-2临床分离株在体外对整合酶抑制剂拉替拉韦和埃替格韦的表型敏感性
J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20.
8
Raltegravir treatment response in an HIV-2 infected patient: a case report.一名HIV-2感染患者的拉替拉韦治疗反应：病例报告
AIDS. 2008 May 31;22(9):1091-2. doi: 10.1097/QAD.0b013e3282f9b165.
9
10
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.2型人类免疫缺陷病毒B亚型血浆病毒载量检测灵敏度的提高
J Clin Microbiol. 2005 Aug;43(8):4234-6. doi: 10.1128/JCM.43.8.4234-4236.2005.
Zotero 插件